Stock Events

Stock Events

Neovacs 

€0
20
+€0+50% Today

Statistics

Day High
0
Day Low
0
52W High
62
52W Low
0
Volume
10,480,064
Avg. Volume
-
Mkt Cap
285,975.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

31OctExpected
Q2 2019
Q3 2019
Q3 2020
Q1 2021
Q3 2021
Q1 2022
Q3 2022
-5.95
-3.21
-0.46
2.28
Expected EPS
0
Actual EPS
-0.2

Financials

-11,636.9%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
832,000Revenue
-96.82MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALNEV.PA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech competes in the development of novel immunotherapies, similar to Neovacs' focus on therapeutic vaccines for autoimmune diseases.
Moderna
MRNA
Mkt Cap19.51B
Moderna is involved in mRNA-based therapies, competing in the broader immunotherapy space which overlaps with Neovacs' work on autoimmune diseases.
Novavax
NVAX
Mkt Cap1.25B
Novavax operates in the development of vaccines for infectious diseases, competing indirectly with Neovacs by targeting immune system responses.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation specializes in small molecule drugs for oncology and inflammation, competing in the therapeutic area of immune modulation like Neovacs.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is known for its monoclonal antibodies and inflammatory disease treatments, directly competing with Neovacs in the immunotherapy field.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk is a leading company in diabetes and biopharmaceuticals, indirectly competing with Neovacs in the broader healthcare and biotech industry.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company focusing on antiviral drugs and other treatments, competing in the immunotherapy and biotech space relevant to Neovacs.

About

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Show more...
CEO
Mr. Hugo Brugiere M.Sc.
Employees
16
Country
FR
ISIN
FR0014010856

Listings

LSE
GB
0W8U.LSE
STU
DE
0LW0.STU
F
DE
0LW0.F
PA
FR
ALNEV.PA

0 Comments

Share your thoughts

FAQ

What is Neovacs stock price today?▼
The current price of ALNEV.PA is €0 EUR — it has increased by +50% in the past 24 hours. Watch Neovacs stock price performance more closely on the chart.
What is Neovacs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Neovacs stocks are traded under the ticker ALNEV.PA.
Is Neovacs stock price growing?▼
ALNEV.PA stock has risen by +20% compared to the previous week, the month change is a -50% fall, over the last year Neovacs has showed a -100% decrease.
What is Neovacs market cap?▼
Today Neovacs has the market capitalization of 285,975.6
What were Neovacs earnings last quarter?▼
ALNEV.PA earnings for the last quarter are -0.2 EUR per share, whereas the estimation was 0 EUR resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Neovacs revenue for the last year?▼
Neovacs revenue for the last year amounts to 832,000 EUR.
What is Neovacs net income for the last year?▼
ALNEV.PA net income for the last year is -96.82M EUR.
How many employees does Neovacs have?▼
As of April 10, 2026, the company has 16 employees.
In which sector is Neovacs located?▼
Neovacs operates in the Health Care sector.
When did Neovacs complete a stock split?▼
The last stock split for Neovacs was on July 18, 2025 with a ratio of 1:1000.
Where is Neovacs headquartered?▼
Neovacs is headquartered in Suresnes, FR.